Unlocking the Future: Mitochondrial Genes and Neural Networks in Predicting Ovarian Cancer Prognosis and Immunotherapy Response

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2025 Feb 20

PMID 39974375

Authors

Zhijian Tang

Yuanming Pan

Wei Li

Ruiqiong Ma

Jianliu Wang

Affiliations

Soon will be listed here.

Abstract

Background: Mitochondrial genes are involved in the tumor metabolism of ovarian cancer (OC), affecting immune cell infiltration and treatment response. We aimed to utilize mitochondrial genes to predict OC prognosis and immunotherapy response.

Methods: The prognosis data, immunotherapy efficacy and next generation sequencing data of OC patients were downloaded from The Cancer Genome Atlas Program (TCGA) and Gene Expression Omnibus (GEO). Mitochondrial genes were sourced from the MitoCarta3.0 database. Seventy percent of the patients were randomly selected as the discovery cohort for model construction, while the remaining 30% constituted the validation cohort for model assessment. Using the expression of mitochondrial genes as the predictor variable and based on the neural network algorithm, the overall survival (OS) time and immunotherapy efficacy (complete or partial response) of the included patients were predicted.

Results: There were 375 OC patients included to construct the prognostic model, and 26 patients were included to construct the immune efficacy model. The average area under the receiver operating characteristic curve (AUC) of the prognostic model was: 0.7268 [95% confidence interval (CI), 0.7258-0.7278] in the discovery cohort and 0.6475 (95% CI: 0.6466-0.6484) in the validation cohort. The average AUC of the immunotherapy efficacy model was: 0.9444 (95% CI: 0.8333-1.0000) in the discovery cohort and 0.9167 (95% CI: 0.6667-1.0000) in the validation cohort.

Conclusions: The application of mitochondrial genes and neural networks shows potential in predicting the prognosis and immunotherapy response in OC patients. And this approach could provide valuable insights for personalized treatment strategies.

References

Li Y, Gong X, Hu T, Chen Y . Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis. BMC Cancer. 2022; 22(1):74. PMC: 8764839. DOI: 10.1186/s12885-021-09166-9. View

Song P, Li W, Guo L, Ying J, Gao S, He J . Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing. Front Immunol. 2022; 13:850745. PMC: 9231585. DOI: 10.3389/fimmu.2022.850745. View

Emmings E, Mullany S, Chang Z, Landen Jr C, Linder S, Bazzaro M . Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer. Int J Mol Sci. 2019; 20(1). PMC: 6337358. DOI: 10.3390/ijms20010229. View

Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J . Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci. 2021; 22(12). PMC: 8234871. DOI: 10.3390/ijms22126532. View

Reyes-Gonzalez J, Armaiz-Pena G, Mangala L, Valiyeva F, Ivan C, Pradeep S . Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015; 14(10):2260-9. PMC: 4596776. DOI: 10.1158/1535-7163.MCT-14-0801. View

Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha J, Ahmad S . Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019; 8(16):7018-7031. PMC: 6853829. DOI: 10.1002/cam4.2560. View

Li W, Lin S, He Y, Wang J, Pan Y . Deep learning survival model for colorectal cancer patients (DeepCRC) with Asian clinical data compared with different theories. Arch Med Sci. 2023; 19(1):264-269. PMC: 9897076. DOI: 10.5114/aoms/156477. View

Li W, Zhang M, Cai S, Wu L, Li C, He Y . Neural network-based prognostic predictive tool for gastric cardiac cancer: the worldwide retrospective study. BioData Min. 2023; 16(1):21. PMC: 10353146. DOI: 10.1186/s13040-023-00335-z. View

Li S, Li W, Ma T, Fu S, Gao X, Qin N . Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. Front Immunol. 2022; 13:1024707. PMC: 9742243. DOI: 10.3389/fimmu.2022.1024707. View

10.

Hellmann M, Ciuleanu T, Pluzanski A, Lee J, Otterson G, Audigier-Valette C . Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22):2093-2104. PMC: 7193684. DOI: 10.1056/NEJMoa1801946. View

11.

Yang C, Xia B, Zhang Z, Zhang Y, Lou G, Jin W . Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020; 11:577869. PMC: 7572849. DOI: 10.3389/fimmu.2020.577869. View

12.

Wang H, Liu J, Yang J, Wang Z, Zhang Z, Peng J . A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. Front Immunol. 2022; 13:943389. PMC: 9393426. DOI: 10.3389/fimmu.2022.943389. View

13.

Katzman J, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y . DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med Res Methodol. 2018; 18(1):24. PMC: 5828433. DOI: 10.1186/s12874-018-0482-1. View

14.

Carbone D, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M . First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(25):2415-2426. PMC: 6487310. DOI: 10.1056/NEJMoa1613493. View

15.

Webb P, Jordan S . Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2016; 41:3-14. DOI: 10.1016/j.bpobgyn.2016.08.006. View

16.

Bajzikova M, Kovarova J, Coelho A, Boukalova S, Oh S, Rohlenova K . Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. Cell Metab. 2018; 29(2):399-416.e10. PMC: 7484595. DOI: 10.1016/j.cmet.2018.10.014. View

17.

Jung M, Russell A, Liu B, George J, Liu P, Liu T . A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Res. 2016; 77(4):971-981. DOI: 10.1158/0008-5472.CAN-15-2906. View

18.

H M van der Velden B, Kuijf H, Gilhuijs K, Viergever M . Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med Image Anal. 2022; 79:102470. DOI: 10.1016/j.media.2022.102470. View

19.

Werner H . BRCA1: An Endocrine and Metabolic Regulator. Front Endocrinol (Lausanne). 2022; 13:844575. PMC: 9009035. DOI: 10.3389/fendo.2022.844575. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View